Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28882232 | 0.80 | CSNK1D (0.45) | KDM4EALDH1A1ALOX15HSD17B10TSHR | |
| SCHEMBL12279519 | 0.80 | CSNK1D (0.45) | KDM4EALDH1A1ALOX15HSD17B10TSHR | |
| SCHEMBL26659825 | 0.78 | CYP2C9 (0.43) | KDM4EALDH1A1ALOX15HSD17B10TSHR | |
| SCHEMBL2301745 | 0.78 | KDM4E (0.77) | KDM4EALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL26601074 | 0.78 | HPGD (0.41) | KDM4EALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL26601076 | 0.78 | HPGD (0.41) | KDM4EALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL17080736 | 0.77 | KDM4E (0.49) | KDM4EALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL31019262 | 0.76 | ALDH1A1 (0.54) | KDM4EALDH1A1HPGDHSD17B10L3MBTL1 | |
| SCHEMBL2324613 | 0.76 | ALDH1A1 (0.54) | KDM4EALDH1A1HPGDHSD17B10L3MBTL1 | |
| SCHEMBL2324922 | 0.76 | ALDH1A1 (0.54) | KDM4EALDH1A1HPGDHSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281483-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | Astellas Engineered Small Molecules US, Incorporated | 2025-09-11 | — | — | US | disclosed |
| EP-4511112-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | Astellas Engineered Small Molecules US, Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023205415-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | MITOBRIDGE INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205415-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | MITOBRIDGE INC. (US) | 2023-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281483-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | TFEB, MITF, CREBBP | KDM4E 2002/4885ALDH1A1 2399/4885HPGD 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.